Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $ANIP
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/11/2024 | $80.00 | Outperform | Leerink Partners |
10/11/2024 | $68.00 | Overweight | Piper Sandler |
3/15/2024 | $80.00 | Overweight | CapitalOne |
8/22/2023 | $60.00 → $73.00 | Buy | H.C. Wainwright |
3/1/2023 | $55.00 | Buy | Guggenheim |
9/7/2022 | $50.00 | Buy | H.C. Wainwright |
11/2/2021 | $60.00 → $65.00 | Outperform | Raymond James |
11/2/2021 | $70.00 | Buy | Truist |
ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March
PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and select members of senior management, will present at two upcoming investor conferences as follows: Raymond James & Associates' 46th Annual Institutional Investors ConferenceTuesday, March 4, 2025, at 1:40pm ET Leerink Partners Global Healthcare ConferenceTuesday, March 11, 2025, at 3:40pm ET The live and archived webcasts will be accessible from the Company's website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be acce
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, February 28, 2025 Time8:00 a.m. ET Toll free (U.S.) 800-579-2543 Conference ID4860276 Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference
PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the Guggenheim Biotech Conference in New York City as follows: Date:Wednesday, February 5, 2025Time:2:00pm ESTWebcast:Click here The live and archived webcast will be accessible from the Company's website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 60 days. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) i
Leerink Partners initiated coverage on ANI Pharma with a new price target
Leerink Partners initiated coverage of ANI Pharma with a rating of Outperform and set a new price target of $80.00
Piper Sandler initiated coverage on ANI Pharma with a new price target
Piper Sandler initiated coverage of ANI Pharma with a rating of Overweight and set a new price target of $68.00
CapitalOne initiated coverage on ANI Pharma with a new price target
CapitalOne initiated coverage of ANI Pharma with a rating of Overweight and set a new price target of $80.00
SVP, CHIEF HR OFFICER Davis Krista sold $60,200 worth of shares (1,000 units at $60.20), decreasing direct ownership by 1% to 68,624 units (SEC Form 4)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
HEAD OF R&D, COO-NOVITIUM OPS Shanmugam Muthusamy was granted 23,936 shares, increasing direct ownership by 35% to 92,588 units (SEC Form 4)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
SVP, HEAD - ESTABLISHED BRANDS Rowland Thomas Andrew was granted 13,056 shares and covered exercise/tax liability with 582 shares, increasing direct ownership by 37% to 46,092 units (SEC Form 4)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN
Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling
FDA Approval for OXYCODONE AND ASPIRIN
Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling
FDA Approval for EZETIMIBE AND SIMVASTATIN
Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling
Alcami Announces CEO Transition
Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran. "On behalf of the Board, I'd like to express gratitude to Bill for his leadership
ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors
-- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately. "We are delighted to add Matthew (Matt) Leonard to our Board of Directors. With his deep leadershi
ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. "Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our priority people and organizational issues. Krista has a long track record of driving organizational effectiveness and delivering results across industries and cultures, most recently with Novartis, where she led global human resources for
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, February 28, 2025 Time8:00 a.m. ET Toll free (U.S.) 800-579-2543 Conference ID4860276 Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section
ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook
For full year 2024, the Company expects total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be at or above the guidance ranges provided on November 8, 2024Rare Disease Segment performed in line with expectations, with Purified Cortrophin Gel net revenues of $197.8 million to $198.4 million for the full year 2024 and ILUVIEN and YUTIQ net revenues of $30.4 million to $31.0 million for the post-acquisition period from September 16, 2024 to December 31, 2024, based on preliminary, unaudited resultsEstablished preliminary financial outlook for 2025, including total net revenues of $739 million to $759 million and adjusted non-GAAP EBITDA of $182 million to $192 mil
ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance
Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net revenues of $52.6 million, an increase of 76.8% year-over-yearNet loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 millionDiluted GAAP loss per share of $(1.27) and adjusted non-GAAP diluted earnings per share of $1.34Completed the acquisition of Alimera Sciences, Inc. on September 16, 2024, adding two commercial assets ILUVIEN® and YUTIQ® with significant growth potential to its Rare Disease portfolioImplemented new capital structure that is expected to reduce interest expense by approximately $39.0 million on an annualized basis (1)Inc
Amendment: SEC Form SC 13G/A filed by ANI Pharmaceuticals Inc.
SC 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SEC Form SC 13D/A filed by ANI Pharmaceuticals Inc. (Amendment)
SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SEC Form SC 13G filed by ANI Pharmaceuticals Inc.
SC 13G - ANI PHARMACEUTICALS INC (0001023024) (Subject)